Phase II Trial of a 2-Hour Infusion of Gemcitabine Plus Carboplatin As First-Line Chemotherapy for Advanced Non-Small Cell Lung Cancer
钱炯,邓晶,徐农,张晓琛,沈朋,郁兰芳,包悍英,石根明,黄穗,方维佳
DOI: https://doi.org/10.1200/jco.2006.24.18_suppl.17099
IF: 45.3
2006-01-01
Journal of Clinical Oncology
Abstract:17099 Background: Prolonged infusion of gemcitabine have shown increased levels of the active triphosphate metabolite that theorically could increase the response rate and toxicity. The objectives of this study were to evaluated the efficacy and safety of this combination of using gemcitabine as a rate infusion of 10 mg/m2 per min with carboplatin in front-line chemonaive patients with advanced NSCLC. Methods: Fifty-four chemonaive patients have been included. 44 were male and 10 female. Median age was 63 years (19–75). 13% had ECOG 0 and 53.7% ECOG 1 and 33.3% ECOG 2. 32 (59.2%) patients had adenocarcinoma, 13 (24.1%) squamous cell, 1 (1.9%) large cell carcinoma, and 8 (14.8%) others. Eight (14.8%) had stage IIIB and 46 (85.2%) stage IV. Treatment was consisted of 1200 mg/m2 gemcitabine given as a 2-hour continuous infusion (10 mg/m2 per min) on days 1 and 8 of each cycle an AUC 5 carboplatin as on day 1, repeating each cycle every 21 days. A total of 223 chemotherapy cycles were administered, with a median of 4 cycles per patient (range 1–6), and 15 (27.8%) patients received all six cycles. Results: Of the fifty-four patients enrolled, all were evaluated for toxicity (according to the WHO scale) and 51 assessed for response (according to the RECIST criteria), the overall response rate (ORR) was 41.2% (95% confidence interval, 28% to 57%), including two complete responses (CRs: 3.9%) and 19 partial responses (PRs: 37.3%). As per the intent-to-treat (ITT) analysis, the ORR was 38.9%. With a median follow-up time of 10.8 months, the median TTP was 5.0 months (range 3.7–6.3 months), median OS time was 11.5 months (range 9.9–13.1 months) and 1-year survival was 41.7% (95% CI 26% to 57%) and 2-year survival was 19.3% (4.4% to 34.2%).The main grade 3–4 toxicity consisted of neutropenia (55.6%) and thrombocytopenia (57.4%).Patients were required platelet transfusion in 27 cycles (12.1%) and haematopoietic growth factors support care in 56 (25.1%) cycles. No bleeding episodes were recorded. Grade 3 nausea/vomiting occurred in 5.6% and grade 1–2 skin rash occurred in 42.6%. Conclusions: Prolonged gemcitabine infusion combined with carboplatin is manageable tolerated and its efficacy is similar to that of other chemotherapeutic schemes used for NSCLC treatment. No significant financial relationships to disclose.